Hypermarcas (OTCMKTS:HYPMY – Get Free Report) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 4,266 shares, an increase of 82.1% from the September 15th total of 2,343 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 20,164 shares, the days-to-cover ratio is currently 0.2 days.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy”.
Read Our Latest Report on HYPMY
Hypermarcas Price Performance
Shares of Hypermarcas stock opened at $5.10 on Thursday. The firm has a fifty day simple moving average of $4.53 and a 200-day simple moving average of $4.39. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. Hypermarcas has a 1-year low of $3.72 and a 1-year high of $5.77. The stock has a market capitalization of $3.59 billion, a price-to-earnings ratio of 10.20 and a beta of 0.65.
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 12.68%. On average, sell-side analysts expect that Hypermarcas will post 0.51 earnings per share for the current year.
Hypermarcas Company Profile
Hypermarcas SA was a Brazilian consumer healthcare company that developed, manufactured and marketed pharmaceutical and healthcare products. Its portfolio included over-the-counter medicines, prescription products, vitamins and other consumer health brands sold through pharmacies and retail channels.
The company was historically associated with well-known Brazilian brands such as Benegrip, Biotônico Fontoura, Doril, Engov and Epocler. Hypermarcas also previously operated in personal care, beauty, household cleaning and other consumer categories, but divested many of those businesses as it concentrated on pharmaceuticals and healthcare.
In 2018, Hypermarcas changed its corporate name to Hypera SA, adopting the Hypera Pharma identity.
See Also
- Five stocks we like better than Hypermarcas
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
